Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company pioneering oral therapies for hereditary angioedema (HAE) through bradykinin B2 receptor antagonism. This page provides investors and healthcare stakeholders with timely updates on clinical developments, regulatory milestones, and corporate news.
Access consolidated reports on deucrictibant's Phase 3 trials (RAPIDe-3, CHAPTER-3), partnership announcements, and financial disclosures. Our news collection features verified press releases and objective analyses of treatment advancements in rare disease therapeutics.
Key content includes updates on HAE treatment efficacy data, manufacturing partnerships, intellectual property developments, and conference presentations. Bookmark this page for direct access to PHVS's latest progress in transforming patient care through innovative oral medication alternatives.
Pharvaris (PHVS) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Alignment with regulatory agencies on the CHAPTER-3 Phase 3 study design for deucrictibant as a prophylactic HAE treatment
- Progression of RAPIDe-3 Phase 3 study for on-demand HAE attack treatment
- Strong financial position with €344 million in cash as of June 30, 2024
- Q2 2024 R&D expenses of €23.1 million, up from €14.7 million in Q2 2023
- Net loss of €29.7 million for Q2 2024, or €0.55 per share
The company continues to focus on executing its clinical studies to establish differentiated data packages for deucrictibant in both on-demand and prophylactic HAE treatment.
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, announced its annual general meeting of shareholders will be held on June 28, 2024, at 15:00 CEST (9:00 a.m. EDT).
The company focuses on developing novel, oral bradykinin B2 receptor antagonists for treating and preventing hereditary angioedema (HAE) attacks.
All pertinent documents and information for the meeting are accessible on Pharvaris’ website under the 'Investors' section, as well as on the SEC’s website. Shareholders interested in attending must register according to the instructions provided in the meeting notice and agenda.
Pharvaris (Nasdaq: PHVS) recently presented data on their oral bradykinin B2 receptor antagonist, deucrictibant, at several congresses. The data from the Phase 2 RAPIDe-1 study showed that a single dose of deucrictibant resolved symptoms of hereditary angioedema (HAE) attacks in 78.6% of participants within 24 hours, compared to 22.4% for placebo. The Phase 2 CHAPTER-1 study found that treatment satisfaction with deucrictibant was higher than placebo and on par with high-efficacy injectable treatments. Pharvaris expects to publish more data from ongoing open-label extensions to further validate the long-term safety and efficacy of deucrictibant. The company aims to position deucrictibant as a best-in-class treatment for HAE and is exploring additional indications and pipeline expansions.
Pharvaris, a late-stage biopharmaceutical company, will present clinical and nonclinical data at three upcoming congresses focusing on their oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks. The abstracts will cover topics like pharmacological profiles, relief of attack symptoms, efficacy, and safety of their treatments. The company aims to showcase their developments in the field and highlight the positive outcomes of their trials.
Pharvaris, a late-stage biopharmaceutical company with the stock symbol PHVS, reported strong financials with €368 million in cash, executing pivotal Phase 3 studies for HAE treatment, and preparing for commercial launch. The company's loss for Q1 2024 was €28.0 million, with R&D expenses at €18.5 million and G&A expenses at €9.8 million.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
